Xvivo Perfusion AB (publ) (LON:0RKL)
London · Delayed Price · Currency is GBP · Price in SEK 184.70
+3.80 (2.10%)
Feb 12, 2026, 4:24 PM GMT
Xvivo Perfusion AB Market Cap
Xvivo Perfusion AB has a market cap or net worth of 477.3 million as of February 12, 2026. Its market cap has decreased by -51.47% in one year.
Market Cap
477.30M
Enterprise Value
463.55M
Revenue
65.47M
Ranking
n/a
PE Ratio
235.31
Stock Price
184.70
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 34.98M to 477.30M, an increase of 1,264.52%. That is a compound annual growth rate of 21.62%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 11, 2026 | 467.69M | -1.47% |
| Dec 30, 2025 | 474.66M | -57.41% |
| Dec 30, 2024 | 1.11B | 37.94% |
| Dec 29, 2023 | 807.93M | 85.88% |
| Dec 30, 2022 | 434.66M | -35.41% |
| Dec 30, 2021 | 672.92M | -16.86% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 229.82B |
| GSK plc | 86.28B |
| Haleon | 36.19B |
| Smith & Nephew | 10.90B |
| Spire Healthcare Group | 800.72M |
| Allergy Therapeutics | 669.42M |
| Craneware | 520.81M |
| Advanced Medical Solutions Group | 466.09M |